Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
Samsung's three biosimilars generate sales of nearly $800 mn in Europe last year - Pulse by Maeil Business News Korea
Samsung Bioepis' Ranibizumab Biosimilar Application Filed With FDA
Samsung Bioepis enters US market for biosimilars of Humira - KED Global
o9 to supply AI-powered IBP platform to Samsung Bioepis
Samsung Biologics to acquire Biogen's stake in Samsung Bioepis
Samsung Bioepis claims No.1 in European adalimumab biosimilar mkt - Pulse by Maeil Business News Korea
PharmaBoardroom - Samsung Bioepis
Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea | Be Korea-savvy
Samsung Biologics - Wikipedia
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
Samsung Bioepis Company Profile: Valuation, Investors, Acquisition | PitchBook
Samsung Bioepis DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP
Samsung Bioepis launches Ontruzant in Brazil
FDA Accepts Ranibizumab BLA From Samsung Bioepis and Biogen
Samsung Bioepis races rivals as EMA accepts Herceptin biosim app | Fierce Biotech
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Amgen withdraws patent suit against Samsung Bioepis
Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets | Be Korea-savvy
Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Yonhap News Agency
Samsung Bioepis Initiates Phase 3 Trial for Denosumab Biosimilar
SAMSUNG BIOEPIS
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada - KED Global
Innovations in Biosimilars: Insights and Trends from Samsung Bioepis - Xtalks
Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO
